Head to Head Review: OmniAb (NASDAQ:OABI) vs. BioNxt Solutions (OTCMKTS:BNXTF)

OmniAb (NASDAQ:OABI) and BioNxt Solutions (OTCMKTS:BNXTF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares OmniAb and BioNxt Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OmniAb	-275.83%	-22.79%	-20.18%
BioNxt Solutions	N/A	N/A	-815.86%

Volatility & Risk

OmniAb has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500. Comparatively, BioNxt Solutions has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Earnings & Valuation

This table compares OmniAb and BioNxt Solutions”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$26.39 million	8.46	-$62.03 million	($0.60)	-2.58
BioNxt Solutions	$20,000.00	3,509.26	-$3.88 million	($0.04)	-15.16

BioNxt Solutions has lower revenue, but higher earnings than OmniAb. BioNxt Solutions is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

72.1% of OmniAb shares are owned by institutional investors. 8.6% of OmniAb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for OmniAb and BioNxt Solutions, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1	0	3	0	2.50
BioNxt Solutions	0	0	0	0	0.00

OmniAb presently has a consensus price target of $6.67, suggesting a potential upside of 330.11%. Given OmniAb’s stronger consensus rating and higher probable upside, analysts plainly believe OmniAb is more favorable than BioNxt Solutions.

Summary

OmniAb beats BioNxt Solutions on 8 of the 14 factors compared between the two stocks.

About OmniAb

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

About BioNxt Solutions

BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.